Skip to content

Investors Overview

Esperion is a late-stage pharmaceutical company passionately committed to developing and commercializing complementary, non-statin, once-daily, oral therapies to lower elevated  low density lipoprotein (LDL) cholesterol for patients with hypercholesterolemia not adequately treated with current lipid-modifying therapies.  Bempedoic acid, a convenient, complementary, cost-effective, once-daily, oral inhibitor of ATP Citrate Lyase (ACLi) brings a targeted mechanism of action to address patients unmet medical needs in a way that is "patient-friendly, physician-friendly, and payer-friendly”.

Esperion has been a publicly traded company since 2013 and is listed on the NASDAQ Global Select Market under the symbol ESPR.

Copyright West LLC. Minimum 15 minutes delayed.

Press Releases

Date Title and Summary
Toggle Summary Esperion Therapeutics Completes $22.75M Series A Financing
Pfizer Inc Spinout of Esperion Therapeutics - Founding Team to Focus on HDL Therapies As a Private Entity
Toggle Summary Esperion Therapeutics Initiates Phase I Clinical Study for ETC-1002
Milestone marks the entry of Esperion into clinical-stage development
Toggle Summary Esperion Therapeutics and Cleveland Clinic Establish Collaboration for Research Related to HDL Therapies
Program involving leading researchers in HDL will work to advance multiple development programs targeting new therapies to treat cardio-metabolic disease.
Toggle Summary TransGenRx Protein Therapeutics Technology to Support Research Related to Protein-Based HDL Therapies at Esperion Therapeutics
Therapeutics developed using TransGenRx advanced protein expression technology to be used in collaborative research at Esperion and Cleveland Clinic targeting new therapies to treat cardio-metabolic disease.
Toggle Summary Esperion Therapeutics Initiates Phase 2 Clinical Study for ETC-1002
Company’s first mid-stage clinical program to focus on patients with dyslipidemia